Mesonephric adenocarcinoma is a rare tumor, accounting for <1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PGP.0000000000000627 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!